Immunoglobulins are still widely prescribed for certain neuromuscular diseases of autoimmune origin, despite the absence of irrefutable scientific evidence. The scarcity of this type of pharmaceutical product has prompted American doctors to reflect on their proper use in neuromuscular diseases:
- the initial consensus drawn up in 2009 by the American Association of Myology (AANEM) was reviewed by a panel of experts;
- this revision included major events in the field, such as the results of clinical trials and/or the approval of certain products by the health authorities;
- all neuromuscular dysimmunity diseases are reviewed.
Immunoglobulins have no place in the long-term treatment of myasthenia gravis or inclusion myositis.
